CFO James M. Frates purchases 40,000 AMLX shares at $2.53, boosting stake 20.7%; part of cluster buy pattern with 2 other insiders in past 14 days
James M. Frates, CFO of Amylyx Pharmaceuticals, purchased 40,000 shares at $2.53 on 2024-09-12, increasing his holding by +20.7% to 233,464 shares total. The transaction occurs as the stock trades 87.2% below its 52-week high, and notably coincides with a cluster pattern in which 2 other insiders also purchased within the past 14 days. AMLX's fundamentals are severely distressed: the latest quarter showed $-1,023,000 revenue and $-72,700,000 net loss, though annual revenue growth is reported at +1612.9% (likely reflecting a recent pivot or acquisition-driven baseline expansion). Frates' prior open-market history shows a 100.00% well-timed rate on sells at the 90-day mark across his cross-ticker track record, signaling disciplined capital allocation decisions; however, his two prior sales at AMLX specifically (both on 2023-05-16) also demonstrated 90-day well-timing, with the stock declining -22.1% and -24.0% after those exits. This buy at a multi-year trough, paired with coordinated insider accumulation, contrasts with his recent history of tactical selling but warrants attention given the company's ongoing cash burn and depressed valuation context.